Olapag 25 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Eltrombopag olamine |
| Company | Drug international ltd |
| Also available as |
Indications
- Treatment of thrombocytopenia in patients with persistent or chronic immune thrombocytopenia
- Treatment of thrombocytopenia in patients with hepatitis C infection
- Treatment of severe aplastic anemia
Pharmacology
Eltrombopag Olamine is a small molecule thrombopoietin (TPO) receptor agonist. Eltrombopag interacts with the transmembrane domain of the human TPO-receptor and initiates signaling cascades that induce proliferation and differentiation from bone marrow progenitor cells finally leading to increased platelet production.
Dosage & Administration
- Route of administration: Oral
- Dosage instructions for various conditions
- Dosing recommendations for different patient populations
Interaction
- Drug interaction with medication
- Drug interaction with food and others
Contraindications
Eltrombopag is contraindicated in patients with known hypersensitivity to eltrombopag or any components of this product.
Side Effects
- Anemia
- Nausea
- Pyrexia
- ALT increased
- Cough
- Fatigue
- Headache
- Diarrhea
Pregnancy & Lactation
No sufficient data is available to assess any drug-associated risks for major birth defects, miscarriage, adverse maternal or fetal outcomes. Breastfeeding is not recommended during treatment.
Precautions & Warnings
- Increased risk of hepatic decompensation
- Increased risk of death and progression of myelodysplastic syndromes to acute myeloid leukemia
- Portal vein thrombosis
- Monitor liver function and platelet counts regularly
Use in Special Populations
- Safety and efficacy in pediatric patients below the age of 1 year with ITP have not been established
- Safety and efficacy in pediatric patients with thrombocytopenia associated with chronic hepatitis C and refractory severe aplastic anemia have not been established
Overdose Effects
In the event of overdose, platelet counts may increase excessively and result in thrombotic or thromboembolic complications. Consider oral administration of a metal cation containing preparation to chelate eltrombopag and limit absorption.
Therapeutic Class
Haemostatic drugs
Storage Conditions
Store in a cool (below 25°C) and dry place protected from light. Keep away from the reach of children.